Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomised withdrawal study

European Journal of Psychiatry

Volumn 27, Issue 3, 2013, Pages 185-205

  Upadhyaya, Himanshu ^a   Ramos Quiroga, J Antoni ^b   Adler, Lenard A ^c   Williams, David ^d   Tanaka, Yoko ^a   Lane, Jeannine R ^d   Escobar, Rodrigo ^a   Trzepacz, Paula ^a   Camporeale, Angelo ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SYNEOS HEALTH   (United States)

Author keywords

ADHD; Adult; Atomoxetine; Attention deficit hyperactivity disorder; European

Indexed keywords

ATOMOXETINE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONNERS ADHD RATING SCALE INVESTIGATOR RATED SCREENING VERSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTPATIENT; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

EID: 84885770183     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0213-61632013000300004     Document Type: Article

References (40)

1. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402-409.
2. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 27(2): 187-201.
3. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63(12): 10-15.
4. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatr. 2000; 48(1): 9-20.
5. Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev 2007; 39(1): 94-105.
6. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005; 162(9): 1621-1627.
7. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009; 29(1): 44-50.
8. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 2010; 30(5): 549-553.
9. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53(2): 112-120.
10. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155(5): 693-695.
11. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57(5): 456-463.
12. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 2003,48(8): 546-554.
13. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind crossover trial. Psychol Med 2004; 34(6): 973-982.
14. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63(10): 981-989.
15. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry 2010; 10: 67.
16. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attentiondeficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 409-432.
17. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992; 15(1): 191-222.
18. Vaughan B, Fegert J, Kratochvil CJ. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2009; 10(4): 669-676.
19. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114(1): e1-e8.
20. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83.
21. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159(11): 1896-1901.
22. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, et al. Results from 2 proofof-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63(12): 1140-1147.
23. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ; Atomoxetine Low-Dose Study Group. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics 2006; 118(6): e1701-e1706.
24. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43(7): 896-904.
25. Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. A randomized, doubleblind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007; 61(5): 694-699.
26. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96(1-2): 145-154.
27. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26(3): 212-221.
28. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems, Inc.; 1999.
29. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education, and Welfare; 1976.
30. Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, et al. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. Clin Ther 2012; 34(2): 363-373.
31. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158(2): 282-288.
32. Brod M, Johnston J, Able S, Swindle R. Validation of the adult attention-deficit/hyperactivity disorder quality-oflife Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res 2006; 15(1): 117-129.
33. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3): 199-208.
34. Roth RM, Isquith PK, Gioia GA. Behavior Rating Inventory of Executive Function-Adult Version. Lutz, FL: Psychological Assessment Resources, Inc.; 2005.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
36. Shaw P, Gogtay N, Rapoport J. Childhood psychiatric disorders as anomalies in neurodevelopmental trajectories. Hum Brain Mapp 2010; 31(6): 917-925.
37. Nakao T, Radua J, Rubia K, Mataix-Cols D. Grey matter volume abnormalities in ADHD: voxel-based metaanalysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011; 168(11): 1154-1163.
38. Buitelaar JK, Trott G-E, Hofecker M, Waechter S, Berwaerts J, Dejonkheere J,. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol 2012; 15(1): 1-13.
39. Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell C, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attentiondeficit/ hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry 2012; 73(7): 977-983.
40. Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 2006; 26(6): 648-652.